DAYBREAK decides the Kodiak story
- Kodiak has no approved products and has not generated revenue, so the stock depends entirely on clinical and regulatory wins.
- Zenkuda, also called tarcocimab, looked much better in diabetic retinopathy after GLOW2 met its main goal with no intraocular inflammation reported.
- The next big test is DAYBREAK, a Phase 3 wet AMD study expected to report topline data in the third quarter of 2026.
- The company recently advanced KSI-501 into the Phase 3 ALTO study for DME, giving it a second late-stage focus.
- The bear case is still real because tarcocimab missed key wet AMD goals in earlier DAZZLE, GLEAM, and GLIMMER trials.
One trial carries the weight
Kodiak is a high-risk retina drug story. The good news is that Zenkuda, its lead drug also known as tarcocimab, has shown it can work with less frequent dosing in diabetic retinopathy. In GLOW2, the drug met its primary endpoint, met secondary goals, and reported no intraocular inflammation.
That matters because retina patients often need repeated eye injections. A drug that can last about six months in the right setting could be valuable if doctors trust the data and regulators approve the label.
The hard part is wet AMD. Tarcocimab already failed to show non-inferior vision gains in the DAZZLE, GLEAM, and GLIMMER wet AMD studies. DAYBREAK is the repair attempt. It uses an enhanced 50 mg/mL formulation and also tests KSI-501, a VEGF and IL-6 blocker.
The thesis is simple. If DAYBREAK is clean and regulators accept the bridge from the old formulation to the go-to-market material, Kodiak may have a real retina franchise. If not, the company is left with earlier programs and a damaged lead asset. A new Phase 3 ALTO trial for KSI-501 in DME adds another path, but DAYBREAK remains the near-term event.
Science first, sales later
Kodiak does not sell an approved product today. It is spending money to run trials, improve drug designs, and prepare for a possible Biologics License Application. That application is the formal FDA filing used for biologic drugs.
The company is built around its ABC Platform. That platform links protein drugs to a biopolymer backbone. The goal is to keep the drug active in the eye for longer. The newer ABCD Platform extends that idea to small molecules and other active ingredients.
If approved, Kodiak would make money from retina drug sales. It could build its own commercial team, use partners, or mix both approaches. Until approval, the business breaks if trial results are weak, regulators reject the data package, or cash runs too low.
Retina shots and new tools
Zenkuda (tarcocimab)
This is the lead anti-VEGF antibody biopolymer conjugate. It has completed GLOW2 in diabetic retinopathy and is in DAYBREAK for wet AMD.
KSI-501
KSI-501 is a first-in-class bispecific conjugate meant to block VEGF and IL-6. It is being studied in DAYBREAK for wet AMD and is actively enrolling the Phase 3 ALTO trial for DME.
KSI-101
KSI-101 is a VEGF-trap and anti-IL-6 bispecific protein for retinal inflammatory disease. The PEAK and PINNACLE Phase 3 studies are enrolling patients, with the first PEAK cohort fully enrolled.
KSI-102 and KSI-103
These are pre-IND ocular inflammation programs. KSI-102 targets TNFa and IL-6, while KSI-103 targets IL-1 and IL-6.
ABCD glaucoma and dry AMD
The ABCD Platform adds preclinical shots on goal in glaucoma and dry AMD. These are early programs testing sustained release with small molecules.
VETi headset
VETi is an AI and machine-learning enabled wearable headset. Kodiak sees it as a possible support tool for a future commercial retina franchise.
One operating segment
Kodiak reports as one operating segment focused on research, development, and possible commercialization of retinal disease therapies. It currently has no approved commercial products and has not generated revenue.
What could break
DAYBREAK misses in wet AMD
High impact · Medium oddsThis is the main near-term risk. Tarcocimab already missed primary wet AMD efficacy goals in DAZZLE, GLEAM, and GLIMMER. Investors need DAYBREAK to show that the new plan fixed the problem.
FDA rejects the formulation bridge
High impact · Medium oddsKodiak changed to an enhanced 50 mg/mL formulation for the go-to-market version of Zenkuda. The FDA advised that added studies should bridge old and new material, but regulators could still disagree when reviewing the actual data.
AI dosing tool creates label friction
Medium impact · Medium oddsDAYBREAK uses an AI-based tool to measure retinal fluid and personalize dosing. Management warns that this dosing approach may not make it into labeling or could require separate FDA review of the AI tool.
Safety signal returns
High impact · Low oddsGLOW2 was encouraging because no intraocular inflammation was reported. Eye drugs have little room for safety surprises, since doctors avoid drugs that risk inflammation or vision harm.
Pipeline options stay too early
Medium impact · Medium oddsKSI-101, KSI-501, ABCD, and VETi add breadth. But most of that value is still not proven by approval or sales. If the lead program stumbles, these assets may not carry the company.
In one breath
Does Kodiak Sciences have any approved products?
No. Kodiak is still a clinical-stage company. Its filings say it has no approved products for commercial sale and has not generated revenue.
What is the main Kodiak Sciences catalyst?
The main catalyst is the Phase 3 DAYBREAK wet AMD readout, expected in late 2026. A positive result could support a planned single BLA across diabetic retinopathy, retinal vein occlusion, and wet AMD.
Why did tarcocimab become controversial?
Tarcocimab showed promise, but it previously failed to meet key wet AMD endpoints in DAZZLE, GLEAM, and GLIMMER. GLOW2 helped the diabetic retinopathy case, but DAYBREAK still has to repair confidence in wet AMD.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 23, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Kodiak Sciences Inc. in Finn's Biotechnology industry ranking.
